| Patented Medicine Prices Review Board Canada | news releases
New Patented Medicine Prices Review Board report provides insight into the market for biologic response modifier agents and compares Canadian treatment costs to international benchmarks
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board (the Board) will hold a public hearing with respect to allegations that Galderma Canada Inc. failed to provide Board Staff with the pricing and sales information required under section 80 of the Patent Act and sections 3 and 4 of the Patented Medicines Regulations.
| Patented Medicine Prices Review Board Canada | news releases
The Honourable Jane Philpott, Federal Minister of Health, today tabled the 2015 Annual Report of the Patented Medicine Prices Review Board with the Clerks of the House of Commons and the Senate.
| Patented Medicine Prices Review Board Canada | news releases
In a decision dated June 23, 2016, Canada's Federal Court dismissed a constitutional challenge brought against the Patented Medicine Prices Review Board (PMPRB), an agency created by the federal government to protect consumers from excessively priced patented medicines.
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board (PMPRB) today launched the first phase of a major consultation initiative that will ultimately change the way the federal government determines whether Canadian patented drug prices are excessive.
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board (PMPRB) will hold a public hearing with respect to allegations that Baxalta Canada Corporation failed to provide the PMPRB with the pricing and sales information required by section 80 of the Patent Act and sections 3 and 4 of the Patented Medicine Regulations.
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board (PMPRB) will hold a public hearing with respect to allegations that Galderma Canada Inc. failed to provide the PMPRB with the pricing and sales information required by section 80 of the Patent Act and sections 3 and 4 of the Patented Medicine Regulations.
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System (NPDUIS) research initiative, today published the most recent edition in a series of reports on generic drug pricing.
| Patented Medicine Prices Review Board Canada | news releases
The Honourable Jane Philpott, Federal Minister of Health, has tabled the 2014 Annual Report of the Patented Medicine Prices Review Board (PMPRB) with the Clerks of the House of Commons and the Senate.
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System (NPDUIS) research initiative, presents Private Drug Plans in Canada, Part 1: Generic Market 2005-2013, the first in a series of three NPDUIS reports that explore issues in private drug plans in Canada.
